Maureen E. Thyne Discusses Ruxolitinib's Impact on Myelofibrosis

Maureen E. Thyne, RPA-C, Weill Cornell Medical College, discusses the impact that ruxolitinib (Jakafi) has had on patients with myelofibrosis.

Since its approval in December 2011, ruxolitinib has improved not only side effects, but also overall survival and quality of life. Five-year data is expected to be reported later this year.